Trial
NCT03990961
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Chicago
Collaborators
Merck Sharp & Dohme LLC
Condition
Diffuse Large B Cell Lymphoma
Intervention
Pembrolizumab
Why stopped
Study was closed early due to slow enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-20